Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Возможности применения коэнзима Q10 в терапии сердечно-сосудистых заболеваний у детей
Возможности применения коэнзима Q10 в терапии сердечно-сосудистых заболеваний у детей
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Ключников С.О., Гнетнева Е.С. Убихинон (коэнзим Q10). Клинические аспекты. Лечащий врач. 2007; 7.
2. Ключников С.О., Гнетнева Е.С. Убихинон. Теория и клиническая практика. Педиатрия. Журнал им. Г.Н.Сперанского. 2008; 3.
3. Molyneux SL, Florkowski CM, Lever M et al. Biological Variation of Coenzyme Q10. Clin Chem 2005; 51 (2): 455–7.
4. Кравцова Л.А., Березницкая В.В., Школьникова М.А. Применение коэнзима Q10 (Кудесана) в клинической практике. Рос. вестн. перинатологии и педиатрии. 2006; 6.
5. Врожденные и наследственные заболевания: руководство по педиатрии. Под ред. П.В.Новикова. М., 2007; с. 542.
6. Wang SB, Weng WC, Lee NC et al. Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr Neonatol 2008; 49 (4): 145–9.
7. Леонтьева И.В. Возможности применения коэнзима Q10 в лечении кардиомиопатий. Вестн. педиатрической фармакологии и нутрициологии. 2007; 4 (1).
8. Bhagavan HN, Chopra RK. Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy. Clin Nutr 2005; 24 (3): 331–8.
9. Manzoli U, Rossi E, Littarru GP et al. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React 1990; 12 (3): 173–8.
10. Kocharian A, Shabanian R, Rafiei-Khorgami M et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol Young 2009; 19 (5): 501–6. [Epub 2009 Aug 25.]
11. Soongswang J, Sangtawesin C, Durongpisitkul K et al. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiology 2005; 26 (4): 361–6.
12. Sander S et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12 (6): 464–72.
13. Langsjoen H et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med 1994; 15 (Suppl.): S165–75.
14. Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997; 18 (Suppl.): S145–51.
15. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999; 9 (2–4): 273–84.
16. Eaton S, Skinner R, Hale JP et al. Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000; 302 (1–2): 1–9.
17. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–72.
18. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62: 873–9.
19. Pinheiro R, Neto M et al. Left Ventricular Systolic Function Assessed by Echocardiography in Children and Adolescents with Osteosarcoma Treated with Doxorubicin Alone or in Combination with Dexrazoxane. Arq Bras Cardiol 2006; 87 (6): 699–706.
20. Shan K, Lincoff A, Yong J. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47–58.
21. Schwartz CL, Hobbie WL, Truesdell A et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. Y Clin Oncol 1993; 11: 1906–10.
22. van Dalen EC, Caron HN, Kremer LC. Prevention of anthracycline-induced cardiotoxicity in children: the evidence. Eur J Cancer 2007; 43 (7): 1134–40.
23. Horino N, Kobayashi Y, Usui T. Elevation of lipid peroxide in children treated with a combination of chemotherapeutic agents including doxorubicin. Acta Paediatr Scand 1983; 72: 549–51.
24. Iarussi D, Auricchio U, Agretto A et al. Protective effect of Coenzyme Q10 on anthracyclines cardiotoxicity: control study in childrenwith acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 1994; 15 (Suppl.): s207–12.
25. Lodi R, Hart PE, Rajagopalan B et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001; 49 (5): 590–6.
26. Kosutic J, Zamurovic D. High-dose beta-blocker hypertrophic cardiomyopathy therapy in a patient with Friedreich ataxia. Pediatr Cardiology 2005; 26 (5): 727–30.
27. Hart PE et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005; 62 (4): 621–6.
28. Aeby A, Sznajer Y, Cave H, Rebuffat E et al. Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency. J Inherit Metab Dis 2007; 30 (5): 827.
29. Каленикова Е.И., Городецкая Е.А., Медведев О.С. Фармакокинетика коэнзима Q10. Рус. мед. журн. 2008; 16 (5): 338–40.
2. Ключников С.О., Гнетнева Е.С. Убихинон. Теория и клиническая практика. Педиатрия. Журнал им. Г.Н.Сперанского. 2008; 3.
3. Molyneux SL, Florkowski CM, Lever M et al. Biological Variation of Coenzyme Q10. Clin Chem 2005; 51 (2): 455–7.
4. Кравцова Л.А., Березницкая В.В., Школьникова М.А. Применение коэнзима Q10 (Кудесана) в клинической практике. Рос. вестн. перинатологии и педиатрии. 2006; 6.
5. Врожденные и наследственные заболевания: руководство по педиатрии. Под ред. П.В.Новикова. М., 2007; с. 542.
6. Wang SB, Weng WC, Lee NC et al. Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr Neonatol 2008; 49 (4): 145–9.
7. Леонтьева И.В. Возможности применения коэнзима Q10 в лечении кардиомиопатий. Вестн. педиатрической фармакологии и нутрициологии. 2007; 4 (1).
8. Bhagavan HN, Chopra RK. Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy. Clin Nutr 2005; 24 (3): 331–8.
9. Manzoli U, Rossi E, Littarru GP et al. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React 1990; 12 (3): 173–8.
10. Kocharian A, Shabanian R, Rafiei-Khorgami M et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol Young 2009; 19 (5): 501–6. [Epub 2009 Aug 25.]
11. Soongswang J, Sangtawesin C, Durongpisitkul K et al. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiology 2005; 26 (4): 361–6.
12. Sander S et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12 (6): 464–72.
13. Langsjoen H et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med 1994; 15 (Suppl.): S165–75.
14. Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997; 18 (Suppl.): S145–51.
15. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999; 9 (2–4): 273–84.
16. Eaton S, Skinner R, Hale JP et al. Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000; 302 (1–2): 1–9.
17. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–72.
18. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62: 873–9.
19. Pinheiro R, Neto M et al. Left Ventricular Systolic Function Assessed by Echocardiography in Children and Adolescents with Osteosarcoma Treated with Doxorubicin Alone or in Combination with Dexrazoxane. Arq Bras Cardiol 2006; 87 (6): 699–706.
20. Shan K, Lincoff A, Yong J. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47–58.
21. Schwartz CL, Hobbie WL, Truesdell A et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. Y Clin Oncol 1993; 11: 1906–10.
22. van Dalen EC, Caron HN, Kremer LC. Prevention of anthracycline-induced cardiotoxicity in children: the evidence. Eur J Cancer 2007; 43 (7): 1134–40.
23. Horino N, Kobayashi Y, Usui T. Elevation of lipid peroxide in children treated with a combination of chemotherapeutic agents including doxorubicin. Acta Paediatr Scand 1983; 72: 549–51.
24. Iarussi D, Auricchio U, Agretto A et al. Protective effect of Coenzyme Q10 on anthracyclines cardiotoxicity: control study in childrenwith acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 1994; 15 (Suppl.): s207–12.
25. Lodi R, Hart PE, Rajagopalan B et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001; 49 (5): 590–6.
26. Kosutic J, Zamurovic D. High-dose beta-blocker hypertrophic cardiomyopathy therapy in a patient with Friedreich ataxia. Pediatr Cardiology 2005; 26 (5): 727–30.
27. Hart PE et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005; 62 (4): 621–6.
28. Aeby A, Sznajer Y, Cave H, Rebuffat E et al. Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency. J Inherit Metab Dis 2007; 30 (5): 827.
29. Каленикова Е.И., Городецкая Е.А., Медведев О.С. Фармакокинетика коэнзима Q10. Рус. мед. журн. 2008; 16 (5): 338–40.
Авторы
А.Н.Горяйнова
Кафедра педиатрии РМАПО, Москва
Кафедра педиатрии РМАПО, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.